Persistent URL of this record https://hdl.handle.net/1887/104431
In Collections
This item can be found in the following collections:
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)
- All authors
- Willemze, R.; Suciu, S.; Muus, P.; Halkes, C.J.M.; Meloni, G.; Meert, L.; Karrasch, M.; Rapion, J.; Vignetti, M.; Amadori, S.; Witte, T. de; Marie, J.P.
- Date
- 2014-06-30
- Journal
- Annals of Hematology
- Volume
- 93
- Issue
- 6
- Pages
- 965 - 975